Evogene Ltd. received a letter from Nasdaq granting an additional 180-day period to regain compliance with the minimum bid price requirement, extending the deadline to March 29, 2027. The company was previously notified on March 30, 2026, that its closing bid price had been below $1.00 per share for 30 consecutive business days. Evogene can regain compliance if its ordinary shares close at least $1.00 for ten consecutive business days during the cure period. Failure to meet this requirement by March 29, 2027, could result in delisting from Nasdaq. The company intends to consider options such as a reverse share split to address the deficiency. Evogene operates in the computational chemistry industry, specializing in generative AI for small molecule design in pharmaceuticals and agriculture.
